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Abstract 
The objectives for this study were to apply four different approaches for disseminating Consumer Reports Best Buy Drugs (CR-BBD) 
information about effectiveness, safety, and cost to patients for therapeutic classes of medications that they were using and then (1) 
evaluate the usefulness of the information to participants and (2) document resultant information seeking. For the three approaches 
that utilized face-to-face contact (Approaches 2 through 4), we also compared them in terms of (1) number of medications reviewed 
per person, (2) availability of CR-BBD information per person, (3) changes that could be made for each person, and (4) potential/likely 
cost savings (per person per month).  Finally, we described the availability of CR-BBD information for each participant categorized by 
the 19 therapeutic classes of medications for which there were Best Buy Drugs reports. Data were collected via self-administered 
surveys, in-person interviews, and telephone interviews. The results showed that almost all of the participants in the information 
sessions held for this study had at least one medication for which Best Buy Drug information was available with significant savings 
potential to be gained by using the recommended Best Buy Drug. Potential cost savings through the use of recommended Best Buy 
Drugs was $89.47 per person per month averaged over all participants (n = 172) and was $157.20 per person per month for those 
with savings over zero dollars (n = 98). Thirty-two percent of respondents to our evaluation survey reportedly sought more 
information from a physician and 30 percent sought more information from a pharmacist.  We concluded that provision of 
information about effectiveness, safety, and cost to patients has the potential for achieving significant cost savings. 
Recommendations regarding (1) the timing of provision, (2) targeting of recipients and (3) traversing impediments are given. 
 
 
Background 
Prescription drugs can be expensive, even if one has 
insurance coverage for them. For many ailments, there are 
prescription drug treatment options that effectively meet 
patients’ medical needs and also give value for their health 
care dollar. However, navigating patients’ drug options in 
light of related costs is difficult due to a lack of information 
on the parts of both prescribers and their patients [1].  
 
Shrank and colleagues reported that many prescribers of 
medications are not aware of patients’ formularies or out-of-
pocket costs for medications, do not feel responsible for 
managing these costs, and prefer a pharmacist’s assistance in 
these matters [2]. A study conducted in Minnesota and North 
Dakota showed that while physicians believed that it is 
important to prescribe drugs that would minimize patients’ 
prescription copayments, they were often unaware of the 
preferred medications on the formulary, patients’ copayment 
amounts, and the price of drugs prescribed [3].  
 
Typically, patients also are unaware of the cost consequences 
regarding prescribing decisions during their clinical encounter 
[4-5] and rarely talk with their physicians about costs of 
prescription drugs [6]. Studies suggest that prescription 
medications that are deemed by patients to be too costly, 
when the costs become known after purchase, are 
discontinued or used at suboptimal doses compared to 
prescription medications that are deemed to be worth the 
cost [7-14]. In addition, those who report cost-related 
adherence problems also have poorer health [14].  
 
Based on these findings, it may be unlikely that cost and 
payment policies established by health plans are ever 
considered during the prescription choice process. Or, if such 
information is considered by one member of the prescriber-
patient dyad, the other member may engage in a behavior 
that nullifies such consideration. A prescription drug 
marketplace that contains fair and balanced information 
about not only the effectiveness and safety of medications, 
but also their affordability, could help prescribers and 
patients make value-based decisions regarding prescription 
drug therapy. However, if such information is not utilized 
during the prescription decision process, inefficient and 
ineffective choices regarding therapy could result.  
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Study Objectives 
The objectives for this study were to apply four different 
approaches for disseminating Consumer Reports Best Buy 
Drugs (CR-BBD) information about effectiveness, safety, and 
cost to patients for therapeutic classes of medications that 
they were using and then (1) evaluate the usefulness of the 
information to participants and (2) document resultant 
information seeking. For the three approaches that utilized 
face-to-face contact (Approaches 2 through 4), we also 
compared them in terms of (1) number of medications 
reviewed per person, (2) availability of CR-BBD information 
per person, (3) changes that could be made for each person, 
and (4) potential/likely cost savings (per person per month).  
Finally, we described the availability of CR-BBD information 
for each participant categorized by the 19 therapeutic classes 
of medications for which there were Best Buy Drugs reports.  
 
Description of Consumer Reports Best Buy Drugs (CR-BBD) 
Information 
The Consumer Reports drug therapy class reviews (Consumer 
Reports Best Buy Drugs) served as the primary information 
source for this project. These reports were prepared based 
primarily upon independent scientific review of evidence in 
the health literature related to the effectiveness, safety and 
adverse effects of specific therapeutic classes. The reports 
relied heavily upon the Oregon Health & Science University’s 
Evidence-based Practice Center and the information provided 
in the extensive therapeutic class reports prepared as part of 
the Drug Effectiveness Review Project (DERP). DERP was a 
first-of-its-kind 14-state initiative to evaluate the comparative 
effectiveness and safety of prescription drugs 
(http://www.ohsu.edu/drugeffectiveness/).  
 
There were three major contributions made by Consumer 
Reports as they converted the DERP reviews (hundreds of 
pages) into Best Buy Drugs reports (“full reports” which were 
10 to 20 pages long and “2 page summaries”):  (1) the 
detailed professional literature was distilled and presented in 
consumer-friendly language, (2) price information was added 
to the reports, and (3) within each therapeutic class, the 
reports identified one or more Consumer Reports Best Buy 
Drugs (CR-BBD) that were recommended as first line therapy 
based on effectiveness, safety and cost. Current reports are 
available to www.CRBestBuyDrugs.org.  
 
Prescription drug price information was obtained from 
Wolters Kluwer Health, Pharmacuetical Aduit Suite
®
. The 
prices in the CR-BBD summaries were national averages for a 
one month supply of the drug based on sales through retail 
outlets. It should be noted that Wolters Kluwer Health was 
not involved in analysis or recommendations made by CR-
BBD. The Consumers Reports Best Buy Drugs methodology is 
described in more detail at www.CRBestBuyDrugs.org. 
Consumers Union, publisher of Consumer Reports magazine, 
is an independent and nonprofit organization whose mission, 
since 1936, has been to provide consumers with unbiased 
information on goods and services and to create a fair 
marketplace. At the time of our study, the Consumer Reports 
Best Buy Drugs program was a public education project 
administered by Consumers Union and supported by the 
Engelberg Foundation, a private philanthropy entity, and the 
National Institutes of Health’s National Library of Medicine. 
At the time of our study, Consumer Reports Best Buy Drugs 
(CR-BBD) reports were available for 19 therapeutic classes 
(Alzheimer’s, angiotensin converting enzyme inhibitors, 
anticonvulsants, antidepressants, antihistamines, 
antiplatelets, antipsychotics, asthma, attention deficit 
hyperactivity disorder, beta blockers, calcium channel 
blockers, diabetes, insomnia, menopause, non-steroidal anti-
inflammatory drugs, overactive bladder, proton pump 
inhibitors, statins, triptans). 
 
Disseminating Consumer Reports Best Buy Drugs (CR-BBD) 
Information in this Study 
Based on a series of nine focus groups with patients, 
prescribers, experts, and patient advocates, [15] we 
confirmed that use of the Internet for accessing health 
information and acceptance of computer-based information 
kiosks placed in public settings were both low among low-
income individuals with high out-of-pocket costs who would 
benefit most from CR-BBD information [16-18]. Furthermore, 
research has shown that simple, one-time educational 
interventions aimed at changing physician behaviors are 
seldom effective [19]. While strategies such as academic 
detailing have been shown to modify prescribing patterns in 
some therapeutic classes [20], they can be prohibitively 
expensive. Consumer education programs have been shown 
to change prescribers’ prescribing patterns [21] and research 
on direct-to-consumer advertising has shown that physicians 
are highly responsive to patients’ requests for medications 
[22-23].   
 
With these previous findings in mind, we sought to use an 
orchestrated approach for disseminating CR-BBD information 
using three integrated strategies: (1) “push” (promoting best 
buy drugs to prescribers through health plan incentives and 
electronic aids used for prescribing), (2) “pull” (encouraging 
patients to ask their prescribers for recommended best buy 
drugs), and (3) “prompt” (timing information dissemination 
during peak relevance such as when patients are waiting for a 
clinic visit, purchasing prescriptions, or considering health 
plan choices). 
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Meetings with health plans revealed that “push” strategies 
were well received by medical directors of health plans, but 
the timing of our study interventions would not allow 
Minnesota health plans to participate in such interventions 
due to (1) other initiatives they already had chosen to 
implement during the study period and (2) rebate contracts 
for prescription medications that already were in place and 
that were not congruent with CR-BBD recommendations. We 
also negotiated with a large employer who was willing to 
employ an orchestrated “push”, “pull”, and “prompt” 
strategy in its company as part of its health care “intranet” 
and self-insured status for health care benefits. However, 
after initial agreement from the employer, the pharmacy 
benefit management consulting company for this employer 
objected to participation in our study due to existing 
contractual prescription drug rebate agreements that were in 
place during the study period. In light of these impediments, 
our interventions primarily employed “pull” and “prompt” 
strategies and were targeted at consumers/patients.  
 
We used four dissemination approaches for distributing 
Consumer Reports Best Buy Drugs (CR-BBD) information: 
 
 1: Minnesota Senior Federation Helpline (Call 
Center) 
 2: Information Sessions held in Community Based 
Locations (Senior Centers, Churches) 
 3: Information Sessions held in Clinical Sites 
(Pharmacies, Clinics) 
 4: Information Sessions held through a University 
(Mini Medical School) 
 
The four dissemination approaches were compared in terms 
of usefulness of the information to participants and resultant 
health behaviors. For the three approaches that utilized face-
to-face contact (Approaches 2 through 4), we also compared 
them in terms of (1) number of medications reviewed per 
person, (2) availability of CR-BBD information per person, (3) 
changes that could be made for each person, and (4) 
potential/likely cost savings (per person per month).  In 
addition, we described the availability of CR-BBD information 
for each participant categorized by the 19 therapeutic classes 
of medications for which there were Best Buy Drugs reports. 
Each of the four dissemination approaches is described next. 
 
Approach 1: Minnesota Senior Federation Helpline (Call 
Center) 
The Minnesota Senior Federation (MSF) was a statewide 
alliance of mature Minnesotans committed to enhancing the 
quality of their lives. The goal of this organization was to 
equip its members to be their own best advocates regarding 
concerns relating to access to prescription drugs, affordable 
housing, Medicare reform, and changes to Social Security. In 
an effort to disseminate Consumer Reports Best Buy Drugs 
(CR-BBD) information throughout Minnesota, the Minnesota 
Senior Federation (MSF) worked in coordination with the 
University of Minnesota, the Governor’s office, and state 
health associations through press conferences, its Health Plan 
Information Center helpline (HPIC), publications (estimated 
cumulative circulation of 200,000 during the study period), 
and outreach events (an estimated 44,000 people reached 
during the study period).  As people called HPIC for 
information, they were counseled on how to use CR-BBD 
information, mailed a pamphlet on the reports, and provided 
with 2-page summaries for any specific drug categories they 
requested. The HPIC routinely included the CR-BBD 
information when it received calls from Medicare recipients 
who had hit the ‘donut hole’ coverage gap in their Medicare 
Part D plans or were trying to stay out of this coverage gap. 
 
For this project, Approach 1 employed a “pull” strategy 
through which patients (consumers) were informed about 
Consumer Reports Best Buy Drugs and encouraged to “talk 
with their health care provider” about changing to a best buy 
CR-BBD. It also employed a “prompt” strategy in that it timed 
the CR-BBD information dissemination with decisions about 
Medicare Part D health plan choices and avoidance of the 
‘donut hole’ within the Medicare Part D program. During the 
time of our project, 129 individuals contacted the Minnesota 
Senior Federation Helpline and requested information about 
CR-BBD. As part of our evaluation, each of these individuals 
was mailed a survey form asking him or her to provide 
feedback about the usefulness of the information. A 
description regarding the diversity and numbers of persons 
reached by this intervention method is summarized in Table 1. 
 
Approach 2: Information Sessions held in Community Based 
Locations (Senior Centers, Churches) 
In order to provide a face-to-face, personal approach for 
providing the Consumer Reports Best Buy Drugs information, 
12 “information sessions” were held at 12 community centers 
(church or senior center locations). These information 
sessions were scheduled by the Minnesota Senior Federation 
using community based locations with which they already 
had a relationship. Advertising for the information sessions 
was made by both the community-based location and by 
Minnesota Senior Federation using newsletters, flyers, and 
word-of-mouth promotion. This intervention strategy 
employed similar “pull” and “prompt” strategies as outlined 
for Approach 1. What was unique about Approach 2 was the 
face-to-face, one-on-one, personal interaction it provided. 
 
Information sessions were held during two hour time periods. 
Appointments were accepted, but not necessary for 
Original Research COMMUNITY ENGAGED SCHOLARSHIP 
 
http://z.umn.edu/INNOVATIONS                      2013, Vol. 4, No. 2, Article 111                           INNOVATIONS in pharmacy   4 
 
participation. For rare cases when people had to wait 
because all available one-on-one sessions were filled, 
refreshments and sitting areas were available. Also, we had a 
table with health and insurance information for people to 
peruse using hard copies or a portable computer. Each 
session was staffed by members of the project team including 
a principal investigator, research assistants, University of 
Minnesota staff, and Minnesota Senior Federation Staff. 
Stand-alone display banners, tables, written materials, and 
computer-accessible information sources were brought to 
each session by research personnel. The photo below was 
taken at one of our information sessions held in a community 
location. 
 
 
 
At each information session, the following procedures were 
used: 
 Warm Welcome – greet with a smile and take time to 
listen.  
 Information – provide information about Consumer 
Reports – Best Buy Drugs (CR-BBD) and any 2-page 
information sheets that the person might want. Stress 
the importance of talking with their pharmacist and 
their physician for advice. What we are providing is 
information only and not advice. Their pharmacist and 
physician are able to give advice that will fit with their 
particular health care needs and within their health 
care plan guidelines. 
 Evaluation – ask each person to take a survey form 
with them and take some time to fill it out as a way to 
help us improve how we distribute this information. 
After completing the survey, they can return their 
forms in the postage paid envelope we provided. 
 Questions – ask if there are any questions and invite 
them to contact us at anytime with questions they 
might have. 
 Fond Farwell – make sure materials are easy to carry 
and offer to put them in a bag. Give contact 
information so that they can call us with questions. 
 
 Record Keeping – complete the record form so that we 
can document our activities in terms of (1) what was 
given to each individual, (2) questions that were asked, 
(3) time it took, and (4) any notes about the encounter. 
 
Ninety-eight individuals participated in a one-on-one 
information session at the community based locations. A 
description regarding the diversity and numbers of persons 
reached by this approach is summarized in Table 1. 
 
Approach 3: Information Sessions held in Clinical Sites 
(Pharmacies, Clinics) 
The third approach we employed used the same procedures 
used for Approach 2. However, for Approach 3, the 
information sessions were held in clinical sites (pharmacies, 
clinics). Clinical sites were recruited through the use of the 
Minnesota Pharmacy Practice-Based Research Network 
(PBRN). The Minnesota Pharmacy PBRN is a group of 
pharmacy practice sites devoted principally to the primary 
care of patients, affiliated with each other through a 
partnership with the University of Minnesota and Minnesota 
Pharmacists Association in order to investigate questions 
related to community based practice. The focus of such a 
network is on collecting information in real-world settings 
(pharmacies) to help address societal, community, or 
professional questions that relate to medication use [24]. 
 
Five locations were used for this approach. Three of the 
locations were within a pharmacy (an example of one of 
these locations is in the photo below).  
 
 
 
Two of the locations were within a clinic waiting area, with a 
pharmacy (and pharmacist) adjacent to the waiting area (an 
example of these locations is in the photo on the next page). 
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. 
This approach employed a similar “pull” strategy as outlined 
for Approach 2. However, the “prompt” strategy for this 
intervention was unique in that the information sessions were 
located in clinics (access to prescribers if the person had a 
clinic appointment) and pharmacies (access to pharmacists; no 
appointment needed). 
 
Twenty-four individuals participated in a one-on-one 
information session at the community based locations. 
Thirteen of these participants were at a pharmacy-only 
location and 11 were at a clinic (with pharmacy) location. A 
description regarding the diversity and numbers of persons 
reached by this intervention method is summarized in Table 
1. 
 
Approach 4: Information Sessions held through a University 
(Mini Medical School) 
Information sessions also were held at a University of 
Minnesota Academic Health Center event called “mini 
medical school.” Mini Medical School is “an opportunity for 
community members to experience life as a student in the 
Academic Health Center and learn from world-class clinicians 
and researchers at the University of Minnesota.” Mini 
Medical School students participate in a five-week 
exploration into topics related to health in language everyone 
can understand. 
 
Out of approximately 200 individuals who regularly attended 
the sessions for “mini medical school,” 50 individuals 
participated in an information session at the mini medical 
school event. Procedures for the information session were 
similar to those used for Approaches 2 and 3 except that for 
Approach 4, the information session was announced during a 
mini medical school class two weeks ahead of time so that 
those interested could submit their requests for information 
about medications in writing. That way, packets of Consumer 
Reports Best Buy Drugs information were prepared ahead of 
time and available for distribution during the information 
session.  
 
This approach employed similar “pull” and “prompt” 
strategies as outlined for the other approaches. However, 
what was unique about Approach 4 was the ability to request 
the information ahead of time and then have it delivered in a 
face-to-face, one-on-one, manner. A description regarding 
the diversity and numbers of persons reached by this 
approach is summarized in Table 1.  
 
It should be noted that each of the four approaches described 
provided unique advantages for reaching different segments 
of the population. Table 1 shows that Approach 1 (HelpLine) 
participants were the oldest, on average, and had the highest 
proportion of males (31%) of any of the four approaches. 
Approach 2 (Community) participants were the group that 
had some people without any health insurance (13%) 
compared with other groups that had none. As a reference, 
Minnesota Department of Health estimates for the study 
period showed that only 7% of Minnesotans were without 
health insurance. Sixty-three percent of the Minnesota 
population had health insurance through an employer, 25% 
through public programs, and 5% through individual-
purchased private insurance. 
 
Approach 3 (Clinical Site) participants were distinguished 
from the other three groups in that they reported (1) the 
lowest annual income on average ($29,000), (2) the highest 
number of prescription medications taken daily (7.2), (3) poor 
health more often (40%) than other groups, and (4) 
purchasing medications causes financial hardship the most 
(60%). Approach 4 (University) participants were 
distinguished from the other groups in that they reported (1) 
highest annual income ($110,000), (2) lowest daily 
prescription drug use (2.7), (3) highest Internet use (2.5 hours 
per day), and (4) excellent health more often (29%) than 
other groups. In summary, the four approaches employed 
both “pull” and “prompt” strategies for disseminating 
Consumer Reports Best Buy Drugs information and reached 
different groups of individuals.  
 
Study Methods 
As outlined earlier, 129 individuals requested CR-BBD 
information from a free, consumer HelpLine hosted by the 
Minnesota Senior Federation and face-to-face information 
sessions were held at 12 community centers (church or senior 
center), five clinical sites (three stand-alone pharmacies and 
two pharmacies located within a clinic building), and one 
university academic health center event called “mini medical 
school.” Ninety-eight individuals participated in an 
information session at the community centers, 24 individuals 
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participated in an information session at a clinical site, and 50 
participated in an information session at the university’s mini 
medical school event. 
 
The four approaches were compared in terms of usefulness 
of the information to participants and resultant health 
behaviors. For this analysis, we collected data using an 
evaluation survey that was distributed to the 301 participants 
(129 + 98 + 24 + 50). In addition to the self-administered 
survey, we received permission from 23 participants to 
contact them for an in-depth telephone interview. During the 
interview, we sought to gain insight about the usefulness of 
the Consumer Reports Best Buy Drugs information by asking 
open-ended questions about their reactions to and use of the 
information. 
 
For the three approaches that utilized face-to-face contact 
(Approaches 2 through 4), documentation forms were 
completed for each participant (n = 172) and served as the 
data source for our analysis regarding (1) number of 
medications reviewed per person, (2) availability of CR-BBD 
information per person, (3) changes that could be made for 
each person, and (4) potential/likely cost savings (per person 
per month). In addition, we described the findings 
categorized by the 19 therapeutic classes of medications for 
which there were Best Buy Drugs reports. Data were analyzed 
using descriptive statistics. 
 
Results 
Usefulness of Information and Resultant Information 
Seeking for Approaches 1 through 4 
Evaluation Surveys 
Out of the 301 evaluation surveys distributed to study 
participants, 47 (16 percent) were returned. The distribution 
of the surveys was kept anonymous which precluded any 
follow-up with survey recipients. None-the-less, findings from 
the surveys provide insight regarding the effectiveness of the 
interventions. Response rates for each participant type were 
21% from clinical sites, 16% from community center 
locations, 15% from the consumer help-line group, and 14% 
from the mini medical school location.  
 
Overall, 87 percent of the respondents found the Best Buy 
Drug information somewhat or extremely useful, with the 
remaining 13 percent finding the information not useful at all. 
Fifty-percent of respondents from the mini medical school 
location found it not useful at all, followed by eight percent of 
the helpline participants, six percent of community center 
participants, and zero percent of clinical site participants 
finding the information “not useful at all.” 
 
After receiving the information provided in this study, 32 
percent of respondents reportedly asked their physician a 
question about the recommended Best Buy Drugs and 30 
percent asked their pharmacist a question. Sixty percent of 
the clinical site participants asked their physician a question, 
followed by 39% of helpline participants, 31% of community 
center participants, and 0% of the mini medical school 
participants. Forty percent of the clinical site participants 
asked their pharmacist a question, followed by 38% of 
community center participants, 23% of helpline participants, 
and 17% of the mini medical school participants. Forty 
percent of the clinical site participants asked both their 
physician and pharmacist a question, followed by 25% of 
community center participants, 23% of helpline participants, 
and 0% of the mini medical school participants. The 
proportion of participants reportedly asking a question of 
neither their physician nor pharmacist was: 83% of mini 
medical school participants, 61% of helpline participants, 56% 
of community center participants, and 40% of clinical site 
participants. 
 
Telephone Interviews 
As mentioned earlier, 23 out of the 301 participants in this 
study provided permission to our research team to contact 
them for in-depth telephone interviews at a later date. These 
interviews were used to gain further insights about the 
usefulness of information we provided and resultant health 
behaviors.  Specifically, we focused on the following four 
questions: (1) What is your reaction to the information you 
received? (2) Did you use this information? (3) Did you talk 
with someone about the information? If yes, who? and (4) Do 
you think your health care providers should use this 
information? A summary of results is presented next.   
  
1. What is your reaction to the information you received?  
The interview participants’ reactions to the Consumer 
Reports Best Buy Drugs information were very positive 
overall, with the majority of participants reporting positive 
comments about the information. Examples of verbatim 
comments included: 
 
 Wonderful information.  Glad that somebody is 
aware of people wanting to cut the cost of their 
meds and still feel like they are being helped. 
 Thought it was a really good idea; latched onto the 
idea right away; compared what they show to what I 
take.   
 Good idea for everybody to be informed about.   
 Terrific information 
 Welcome the information, I really like to have a place 
where I can go look for the information.  
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 Very impressed; good way to get information. 
 Thought it was helpful. 
 I was very impressed with the information.  I thought 
it was very positive. 
  
Two respondents had reactions that were not positive.  One 
person was concerned that the information was not complete 
/ thorough enough and one person felt that the information 
was complicated.  Finally, four respondents had neutral 
reactions: (1) one participant had no reaction and “wished 
she was more knowledgeable”; (2) one participant was 
unfamiliar with the program and did not remember attending 
an information session; (3) one participant did not recall the 
information; and (4) one participant felt the information did 
not apply to her.  
  
2. Did you use this information?  
Six out of the 23 interviewees reported they were able to use 
the Consumer Reports Best Buy Drugs (CR-BBD) information.  
One of these six reported that “Information was used; HMO 
provides information and is on top of things; Health plan is 
working with the consumer to drive down costs.”  A second 
participant reported using the information to get his 
medication switched to a CR-BBD (from Prevacid to 
omeprazole).  However, a third participant could have 
changed to a CR-BBD but did not: “I was able to use the 
information. Compared the drugs that I was taking with those 
shown on the charts to see if there is a less costly substitute.  
I could have changed 20% of my medications, but I didn’t 
change any of them.”  This same participant was the one who 
had concerns about the completeness and thoroughness of 
the Best Buy Drug information (see question #1 above).   
 
Five out the six participants who reported they were able to 
use the CR-BBD information reported that they were already 
on a CR-BBD and were reassured knowing that they were 
taking a “best buy.”  For example, a participant stated that 
she “was able to use the information and it was reassuring to 
know that some of the medications that we are taking were 
best buys even though we thought they were expensive.”  
Another participant reported being “quite pleased with the 
information and she asked her pharmacist to check if she was 
receiving the best buy, reassuring that she was already 
getting the best buy.”  Yet another participant agreed that it 
is “important to find out that I was taking the best buy on the 
medications that I was on, except for one in which no generic 
was available. But my thought was why try something else 
when you found something that works (depression 
medication).”  
 
Eight of the 23 interviewees reported that they were unable 
to use the CR-BBD information.  Two participants reported 
that most or all of their drugs were generic, one citing that 
her drugs were “fairly low in cost.”  Four participants stated 
there was no CR-BBD information for medications they were 
currently taking.  For example, one participant stated “In my 
case, person was helpful that reviewed medications, but no 
information on any drugs that I was taking.”  Similarly, 
another participant said “nothing she was taking was on the 
list, so she lost interest right there.” She further elaborated 
that “health insurance has a formulary, so she can’t really 
argue much; the decision is made by the formulary and she 
goes with that first, “ and that you “don’t know what’s on the 
formulary until you get to the pharmacy to get it filled and 
possibly pay for it.”  The final two interviewees (out of the 
eight) didn’t provide any specific reasons for why they were 
unable to use the information.  
  
3. Did you talk with someone about the information? If yes, 
who?  
Six participants reported sharing the CR-BBD information with 
their social network of family, friends, and neighbors.  One 
participant even handed out and promoted CR-BBD 
information to his retirees’ club.  Two participants reported 
they shared this information with their doctor and 
pharmacist, with one of these participants stating that the 
physician and pharmacist were “impressed as well.”  
Additionally, one person shared the information with his 
physician only.  One of the participants who shared the CR-
BBD information with his doctor perceived that his “doctor 
was receptive to the information, but it was awkward 
because I feel like I was wasting his time on nickels and dimes 
with something he may not feel is worthwhile.  I think his 
time is more valuable.”  Nine participants did not share the 
CR-BBD information with anyone, with one participant 
reporting that “other people had told her about the best 
buy.”   
 
4. Do you think your health care providers should use this 
information? 
The majority of participants agreed that it was important for 
their healthcare providers to use the CR-BBD drug 
information. Examples of verbatim comments included: 
 
 Assumes the healthcare providers are using the 
information and if they aren’t, they better be. 
 Healthcare providers should, but doesn’t think they 
do; don’t have time to do so; others need to help out; 
doctors don’t have control over cost of medications. 
 Great for healthcare providers to use and 
communicate to seniors (send out a mailing). 
 Important for healthcare providers to use; I don’t 
know why they wouldn’t. 
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 Important for healthcare providers to use 
information and become more informed about 
medications.  
 
Only three participants stated that healthcare providers 
should not use the Consumer Reports Best Buy Drugs 
information.  Two participants felt that “healthcare providers 
have their own information” or “healthcare providers seem 
to already have a lot of information” and one participant felt 
that the “information was not helpful to him, so the 
healthcare provider wouldn’t be able to use it either.”   
 
In summary, our sample of interview participants (n=23) 
generally had positive reactions to the Consumer Reports 
Best Buy Drugs information, with many viewing it as helpful 
and useful information.  Participants who already were taking 
a CR-BBD seemed to be “reassured” in knowing this. 
However, we did detect that, for some people, the 
information may be viewed as incomplete or not thorough 
enough. For others the information may be viewed  as being 
too complicated.  
 
Findings for the Three Approaches that Used Face-to-Face 
Interaction 
Face-to-face information sessions were held at 12 community 
centers (church or senior center), one university event called 
“mini medical school”, and at five clinical sites. Ninety-eight 
individuals participated in the one-on-one information 
session at the community centers, 50 participated in an 
information session and the mini medical school event, and 
24 individuals participated in an information session at a 
clinical site, for a total of 172 people.  
 
An average of 10.2 minutes was spent with each participant 
with an average of 5.4 medications reviewed per participant. 
Of the 172 participants, 152 (88%) had at least one 
medication for which Consumer Reports Best Buy Drugs (CR-
BBD) information was available (range = 0 to 9; mean = 2.6 
per participant). Furthermore, 100 (58%) of the participants 
had at least one medication that potentially could be changed 
to a recommended CR-BBD (range = 0 to 5; mean = 1.0 per 
participant). After factoring participants’ comments about 
previous medications in the category that were tried, side 
effects, allergies, or other information that might prohibit the 
use of a recommended CR-BBD, it was determined that  94 
(55% of 172 participants) had at least one medication that 
likely could be changed to a recommended CR-BBD. 
 
Figure 1 provides a summary by location type for number of 
medications reviewed, availability of CR-BBD information, 
and changes that could be made. The findings showed that 
participants at clinical sites presented with the highest 
number of medications for review (mean = 7.9). Both the mini 
medical school event and clinical sites resulted in slightly 
higher numbers of recommendations for CR-BBD (1.3 and 1.2, 
respectively) compared to the community center locations 
(0.7 per person). 
 
Potential cost savings through the use of recommended Best 
Buy Drugs was $89.47 per person per month averaged over 
all participants (n = 172) and was $157.20 per person per 
month for those with savings over zero dollars (n = 98). After 
factoring in participants’ comments about previous 
medications in the category that were tried, side effects, 
allergies, or other information that might prohibit the use of a 
recommended CR-BBD, “likely” cost savings was $83.20 per 
person per month for all participants (n = 172) and $155.75 
per person per month for those with potential savings greater 
than zero dollars (n = 93). 
 
Figure 2 provides a summary for potential and likely cost 
savings (per person per month) by location type. Both mini 
medical school and clinical sites resulted in higher potential 
cost savings ($129.48 and $107.38, respectively) compared to 
community center locations ($64.66).  Mini medical school 
participants had the highest likely savings per person 
($129.48) followed by clinical sites ($99.04), and community 
center locations ($55.71). It should be noted that the mini 
medical school estimates remained the same since we were 
not able to talk with those participants about previous 
medications in the category that were tried, side effects, 
allergies, or other information that might prohibit the use of a 
recommended CR-BBD. 
 
Table 2 provides a summary of findings categorized by the 19 
therapeutic classes included in our study. The findings are 
presented in terms of: (1) proportion of participants who 
were taking a medication in the listed therapeutic class and 
were already taking a recommended CR-BBD, (2) proportion 
of participants who were taking a medication in the listed 
therapeutic class and were NOT taking a recommended CR-
BBD, and (3) proportion of participants who were NOT taking 
a medication in the listed therapeutic class. The findings show 
that, during the time of this study, statins, proton pump 
inhibitors (PPIs), and antidepressants were the therapeutic 
classes with the most cost-savings potential for study 
participants if changes were made to a recommended CR-
BBD. These findings are similar to those reported by Kjos and 
colleagues as another part of this research project [25]. They 
estimated cost savings for members of eight health plans in 
Minnesota and also reported that the most potential for costs 
savings was in the statin, PPI, and antidepressant therapeutic 
classes.  
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Discussion  
The results should be viewed with the study’s limitations in 
mind. Our study was conducted in only one state 
(Minnesota). This state might be different than other states in 
terms of access to healthcare, insurance coverage for 
healthcare, and patient characteristics.  Next, all participants 
volunteered for this study and therefore may have been 
more knowledgeable than non-participants with respect to 
the topic. There may have been some researcher bias due to 
experience and training. Information obtained from study 
participants could be categorized in more than one way and 
research bias could have affected results. However, every 
effort was made to control this by maintaining a neutral 
position and following study protocols. Finally, this study 
included four dissemination approaches. A more extensive 
study with different approaches may reveal more salient 
insights not uncovered in this analysis.  
 
The objectives for this study were to apply four different 
approaches for disseminating Consumer Reports Best Buy 
Drugs (CR-BBD) information about effectiveness, safety, and 
cost to patients for therapeutic classes of medications that 
they were using and then (1) evaluate the usefulness of the 
information to participants and (2) document resultant health 
behaviors. For the three approaches that utilized face-to-face 
contact (Approaches 2 through 4), we also compared them in 
terms of (1) number of medications reviewed per person, (2) 
availability of CR-BBD information per person, (3) changes 
that could be made for each person, and (4) potential/likely 
cost savings (per person per month).  Finally, we described 
the findings categorized by the 19 therapeutic classes of 
medications for which there were Best Buy Drugs reports.  
 
The four approaches that were used in this study included: (1) 
a Helpline (call center), (2) Information Sessions held in 
Community-Based locations (senior centers, churches), (3) 
Information Sessions held in Clinical Sites (pharmacies, 
clinics), and (4) Information Sessions held through a 
University (Mini Medical School). There were 129 study 
participants who used the Helpline, 98 who attended the 
Community-Based location, 24 who attended a Clinical Site, 
and 50 who participated in the Information Session held at 
the University Mini Medical School. Characteristics of 
participants in terms of age, gender, education, income, 
medication use patterns, health status, financial hardship, 
perceived usefulness of the information provided, and 
resultant health behaviors differed among the four 
dissemination approaches used in our study (see Table 1).  
 
Findings from self-reported evaluations from 47 participants 
and in-depth interviews with 23 participants revealed that 
most, but not all, participants generally had positive reactions 
to the Consumer Reports Best Buy Drugs information, with 
many viewing it as helpful and useful information. Overall, 87 
percent of the respondents to our evaluation survey found 
the information somewhat or extremely useful, with 32 
percent seeking more information from a physician, and 30 
percent seeking more information from a pharmacist.  Some 
participants learned about alternative medications they could 
change to that were effective, safe, and less costly than what 
they currently were using. Others reported being reassured in 
knowing that they already were taking a Best Buy Drug for 
their health condition. However, we did detect that, for some 
people, the information was considered incomplete and not 
thorough enough and for others it was too complicated. 
 
Face-to-face information sessions were held at 12 community 
centers (church or senior center), one university event called 
“mini medical school”, and at five clinical sites. Ninety-eight 
individuals participated in the one-on-one information 
session at the community centers, 50 participated in an 
information session and the mini medical school event, and 
24 individuals participated in an information session at a 
clinical site, for a total of 172 people. The results showed that 
almost all of the participants in these three types of 
information sessions had at least one medication for which 
Best Buy Drug information was available with significant 
savings potential to be gained by using the recommended 
Best Buy Drug. The findings also revealed that the statins, 
proton pump inhibitors, and antidepressants were the 
therapeutic classes with the most potential for cost savings if 
changes were made to a recommended Consumer Reports 
Best Buy Drug.  These findings are consistent with a study 
conducted by Kjos and colleagues [25] in which they 
estimated the potential for cost-savings if the drug 
formularies for eight major health plans in Minnesota were 
modified to be more aligned with Consumer Reports Best Buy 
Drugs recommendations. They also found that the most 
potential for costs savings was in the statin, proton pump 
inhibitor, and antidepressant therapeutic classes. 
 
Based on our findings, we propose three recommendations. 
The first two recommendations focus on patient 
characteristics and the last recommendation focuses upon 
organizational and system characteristics. 
 
Recommendation 1: Consider the timing/orchestration of 
when and how evidence based information is provided 
The nature of decision-making, interactions, and expectations 
between prescribers and patients when choosing prescription 
drugs is a dynamic, multi-faceted process [15]. Information is 
used before visiting the clinic, during the clinic visit, at the 
pharmacy, during the initiation phase of taking the 
medication, during the maintenance phase of taking the 
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medication, and during the termination phase of medication 
use. Information about medications’ effectiveness, safety, 
and costs might be useful at each phase of the prescription 
choice and use processes, but, depending upon the 
individual, different timing may be necessary to maximize the 
information’s usefulness. 
 
For example, The adaptive decision making model [26] posits 
that individuals adjust their information-processing and 
decision-making strategies depending upon the complexity of 
information and the context within which decisions must be 
made. Research suggests that rather than processing more 
information when decisions become more complex, 
individuals tend to reduce the amount of effort they expend 
on decision-making [26].  Also, individuals tend to use 
information more extensively if it costs them less in time, 
money, or effort to acquire it. Another principle of the 
adaptive decision making model is that both too little and too 
much information result in poorer decision-making when 
compared with the right amount of information. Finally, 
individuals with a moderate level of knowledge search for 
information the most before making a decision. That is, those 
with low levels of knowledge don’t have the ability and those 
with high levels of knowledge don’t have the motivation for 
obtaining more information. 
 
With the adaptive decision making model as a guide, we 
propose that decision-making during initiation of medication 
therapy would be improved if attention were given to 
matching the timing of giving information to patients, their 
caregivers, and their providers to the time when they need it 
for decision-making.  Making all information available at once 
leads to information overload. But, withholding information 
(such as medication cost) until after a prescribing decision is 
made results in poorer decisions.  The optimal approach is to 
provide relevant information at the time that it is needed for 
making decisions. Rather than a unidirectional approach to 
information giving at discrete points in time, patients and 
caregivers would be better served if they were able to submit 
questions in real time as issues arise and then get answers 
and advice immediately. 
 
In addition, we suggest that patients’ styles and preferences 
should be matched with provider styles of care delivery [27-
40].  For example, some patients may seek interactions that 
are advisory, informational, negotiational, relational, or 
none/default at different stages of their medication taking 
experience. According to the Concordance Model [39,40], 
matching needs with suitable providers would improve 
information exchange and decision-making.  
 
Finally, as medication use is initiated, there should be 
feedback loops about effectiveness, safety, cost, and social 
issues as soon as the patient experiences changes in these 
areas [15, 27-40]. Provision of such information at the correct 
time can avert mishaps and lead to better decision-making 
for drug therapy adjustments that would be needed [41,42].  
 
Timing of information, matching preferences and styles, and 
providing feedback can be accomplished through “care in the 
cloud” approaches in which patients, caregivers, and 
providers alike can submit information and send messages to 
a central site through electronic means [43]. Algorithms and 
prompts can be used to match patient needs with provider 
services in real time. We propose that such matching would 
improve the abilities of patients, caregivers, and providers in 
processing information and making decisions. 
 
Recommendation 2: Consider consumer segmentation 
approaches for targeting evidence based information 
In addition to consideration of the timing and orchestration 
of information provision, the use of segmentation models to 
help identify groups that (1) could realize the most 
medication cost savings, (2) are in greatest need, (3) have 
unique social networks for information dissemination, (4) 
present unique challenges/opportunities regarding 
information search, or (5) have differing levels of involvement 
in the process could provide fruitful results. Thus, while the 
first recommendation focuses on the timing of when 
information is provided, this second recommendation focuses 
upon tailoring the information to make it most relevant to 
individual patient’s needs. 
 
For example, the so-called “solution seeker” segment of the 
U.S. health care market [34] might benefit the most from CR-
BBD information. The “solution seeker” segment is about 8% 
of the U.S. adult population and is comprised of people with 
below-average health, who are more inclined than others to 
take preventive medicine, and take active steps in response 
to information about their condition [34]. Solution seekers 
“make it their business to pursue information regarding their 
ailment and educate themselves about potential treatment 
options” [34]. This segment can be contrasted with the 
“doctor led” (28% of adults who share a similarly below-
average health profile with the solution seekers and receptive 
to information but are less proactive in exploring potential 
new treatment options on their own), “self-managers” (13% 
who enjoy above average health with only occasional or 
seasonal health complaints), and members of the “healthy 
half” who are in excellent health and have little interest in 
health information at this time of their lives [34]. Based on 
these findings, we suggest that a “one-size-fits-all” approach 
for applying evidence-based prescribing would not be as 
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fruitful as a segmentation approach in which information is 
tailored to maximize relevance to each patient. 
 
Recommendation 3: Resolve competing incentives created 
by rebates, pay-for-performance, out-of-pocket cost 
differentials, advertising, and government regulations at the 
various stages of prescription choice, to improve the 
efficiency and effectiveness of such decision-making. 
Health care providers and consumers are faced each day with 
decisions regarding prescription medications.  Ideally, these 
decisions are made based on the best information and 
evidence that is available to meet desired patient outcomes.  
However, these decisions are often heavily influenced by 
formulary requirements of various health plans.  Because of 
the high level of regulatory control that formulary systems 
sometimes place on the prescribing of medications, there is a 
need to critically examine the practices of health plans and 
the potential for cost savings through the use of evidence-
based information. 
 
In the U.S., potential signals of market failure for current drug 
benefit designs include: (1) the U.S. free market system has 
the highest drug prices in the world, (2) the U.S. free market 
system has the highest rates of price inflation for 
pharmaceuticals in the world, (3) the largest volume market 
has the highest prices in the world, (4) contracts declare price 
and rebate information as “proprietary and confidential,” (5) 
cost data can not be disclosed to P&T committees or 
physicians, (6) a lack of data for policy and economic 
research, (7) payers and patients do not know the net cost of 
a specific drug, (8) physicians do not know relative or 
absolute price, (9) patients do not know price, and (10) P&T 
committees often do not know price [44].   
 
In addition to these issues, a number of competing incentives 
[44-47] may need to be addressed in the pharmaceutical 
marketplace including: 
 
1. Prescription Benefit Management company (PBM) 
receipt of hidden rebates, not disclosed or passed on 
to payers. 
2. Payers’ focus on percent discount and dispensing 
fees rather than on overall cost when negotiating 
contracts with PBMs. 
3. Drug firm payment for data, research studies, etc. 
that are linked to PBM decision making. 
4. Most revenue for some PBMs coming from drug 
firms than from a health plan or a payer for the 
prescription drug benefit. 
5. Placement of higher priced drugs as preferred on 
formularies based on rebates or on bundling of 
rebates. 
6. Payments by brand firms to generic manufacturers 
to withhold a generic going to market. Generic firm 
receives more than what it could charge in the 
marketplace and the brand firm continues with a 
price at 2 to 10 times the market-based price. 
7. Physicians and clinics making more from Medicare 
on higher cost drugs, which leads to higher priced 
drugs becoming the most prescribed drugs. 
 
There is growing pressure for the health care system to take a 
closer look at evidence-based approaches for prescription 
drug benefits as a strategy to help remedy the issues plaguing 
the pharmaceutical marketplace. We suggest that employer 
groups and other purchasers of health care coverage should 
request more transparency and full disclosure in their 
contract negotiations for health care services. The removal or 
full disclosure of competing incentives such as those outlined 
previously could open the door for wider application of 
Consumer Reports Best Buy Drugs information and other 
evidence-based information and achieve greater value for 
their health care dollar. 
 
Conclusions 
The focus of this study was an evaluation of the Consumer 
Reports Best Buy Drugs (CR-BBD) Outreach Project in 
Minnesota. The results showed that almost all of the 
participants in the information sessions held for this study 
had at least one medication for which Best Buy Drug 
information was available with significant savings potential to 
be gained by using the recommended Best Buy Drug. Thirty-
two percent of respondents to our evaluation survey 
reportedly sought more information from a physician and 30 
percent sought more information from a pharmacist. We 
suggest that ways to improve the effectiveness of the 
Consumer Reports - Best Buy Drugs information even further 
would be to: (1) consider the timing/orchestration of when 
and how evidence based information is provided, (2) consider 
consumer segmentation approaches for targeting evidence 
based information, and (3) resolve competing incentives 
created by rebates, pay-for-performance, out-of-pocket cost 
differentials, advertising, and government regulations at the 
various stages of prescription choice, to improve the 
efficiency and effectiveness of such decision-making. 
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Table 1: Descriptions of Persons Reached and Their Evaluations for Approaches 1 through 4 
(Estimates based upon responses to evaluation survey n = 47) 
 
 
 
Approach 1 
(HelpLine) 
Approach 2 
(Community) 
Approach 3 
(Clinical Site) 
Approach 4 
(University) 
     
Number of persons reached through this 
approach 
129 98 24 50 
Number of respondents to evaluation survey 19 16 5 7 
Average Age (years) 78 68 74 66 
Proportion Female 69% 80% 86% 86% 
Proportion White/Caucasian 92% 87% 100% 86% 
Proportion with More than High School 
Education 
75% 80% 100% 100% 
Average Annual Income $44,000 $52,000 $29,000 $110,000 
Average # Prescription Medications Used 
Daily 
4.5 3.8 7.2 2.7 
Average # OTC Medications Used Daily 3.1 3.5 4.0 2.3 
Average Hours Watching TV per Day 3.0 2.1 3.2 1.4 
Average Hours Listening to Radio per Day 1.6 2.8 1.0 1.0 
Average Hours Reading News/Magazine/Day 2.2 1.4 1.4 1.4 
Average Hours Using Internet per Day 0.2 0.8 0.1 2.5 
Proportion with Health Insurance 100% 87% 100% 100% 
Proportion with Prescription Drug Insurance 100% 87% 80% 100% 
Reported Health Status 
Excellent 
Very Good 
Good 
Fair 
Poor  
 
0% 
23% 
39% 
15% 
23% 
 
 
7% 
27% 
53% 
13% 
0% 
 
0% 
20% 
40% 
0% 
40% 
 
29% 
57% 
14% 
0% 
0% 
Proportion Reporting that Purchasing 
Medications Causes Financial Hardship 
15% 
 
40% 60% 14% 
Proportion Reporting that the Information 
Received was not useful at all 
8% 
 
6% 0% 50% 
Proportion Reporting that they asked their 
physician a question based on the 
information they received 
 
39% 
 
31% 
 
60% 
 
0% 
Proportion Reporting that they asked their 
pharmacist a question based on the 
information they received 
 
23% 
 
38% 
 
40% 
 
17% 
Proportion Reporting that they asked both 
their physician and pharmacist a question 
based on the information they received 
 
23% 
 
25% 
 
40% 
 
0% 
Proportion Reporting that they asked neither 
their physician nor pharmacist a question 
based on the information they received 
 
61% 
 
56% 
 
40% 
 
83% 
Original Research COMMUNITY ENGAGED SCHOLARSHIP 
 
http://z.umn.edu/INNOVATIONS                      2013, Vol. 4, No. 2, Article 111                           INNOVATIONS in pharmacy   15 
 
Table 2: Summary of Findings Categorized by Therapeutic Categories 
(N = 172 participants)  
 
Therapeutic Category 
 
 
 
Yes, and already  
taking a BBD (a) 
 
Yes, and not  
taking a BBD (b) 
 
Not taking any drug 
in this category (c) 
Statin  24% 20% 
 
56% 
Proton Pump Inhibitor (PPI)  9% 18% 
 
74% 
Antidepressant  7% 13% 
 
80% 
Antihistamine 2% 7% 
 
91% 
Menopause  4% 6% 
 
90% 
Diabetes  9% 5% 
 
86% 
Insomnia  4% 5% 
 
91% 
Angiotensin Converting Enzyme (ACE) Inhibitor  25% 3% 
 
72% 
Antiplatelet 20% 3% 
 
77% 
Calcium Channel Blocker  8% 3% 
 
89% 
Non-steroidal anti-inflammatory drug (NSAID) 4% 3% 
 
93% 
Asthma  6% 2% 
 
92% 
Anticonvulsant  5% 2% 
 
93% 
Beta Blocker  33% 1% 
 
67% 
Triptan  1% 1% 
 
98% 
Overactive Bladder  3% 1% 
 
96% 
Attention Deficit Hyperactivity Disorder (ADHD) 1% 0% 
 
99% 
Alzheimer’s 2% 0% 
 
98% 
Antipsychotic  1% 0% 
 
99% 
(a) Proportion of participants who were taking a medication in the listed therapeutic category and were already taking a 
recommended ‘Best Buy Drug.’ 
(b) Proportion of participants who were taking a medication in the listed therapeutic category and were NOT taking a 
recommended ‘Best Buy Drug.’ 
(c) Proportion of participants who were NOT taking a medication in the listed therapeutic category. 
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Figure 1: Summary by Location Type for Number of Medications Reviewed, Availability of  
CR-BBD Information, and Changes that Could be Made. 
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Meds Reviewed = Number of medications reviewed per person. 
BBD Info = Number of medications for which BBD information was available. 
Change to BBD = Number of medications that could be changed to a Consumer Reports–Best Buy Drug (CR-BBD) 
 
 
 
 
 
Figure 2: Potential/Likely Cost Savings (Per Person Per Month) by Location Type 
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